Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cells.


Journal

Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526

Informations de publication

Date de publication:
2022
Historique:
entrez: 9 5 2022
pubmed: 10 5 2022
medline: 11 5 2022
Statut: epublish

Résumé

The extracellular matrix component biglycan (BGN) plays an essential role in various physiological and pathophysiological processes. A deficient BGN expression associated with reduced immunogenicity was found in HER-2/neu-overexpressing cells. To determine whether BGN is suppressed by oncogene-driven regulatory networks, the expression and function of BGN was analyzed in murine and human BGN

Identifiants

pubmed: 35529675
doi: 10.1080/2162402X.2022.2069214
pii: 2069214
pmc: PMC9067524
doi:

Substances chimiques

Biglycan 0
Histocompatibility Antigens Class I 0
RNA, Messenger 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2069214

Informations de copyright

© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.

Déclaration de conflit d'intérêts

No potential conflict of interest was reported by the author(s)

Références

Int J Cancer. 2020 Dec 1;147(11):2996-3006
pubmed: 32415713
Curr Oncol Rep. 2021 Feb 13;23(3):28
pubmed: 33582927
FEBS J. 2010 Oct;277(19):3904-23
pubmed: 20840587
JCO Precis Oncol. 2017;2017:
pubmed: 29850653
Matrix Biol. 2015 Mar;42:11-55
pubmed: 25701227
Proteomics. 2007 Feb;7(3):385-98
pubmed: 17211828
Cell Rep. 2018 Apr 3;23(1):227-238.e3
pubmed: 29617662
Mol Cancer Res. 2013 Nov;11(11):1462-77
pubmed: 24025972
Cell Syst. 2018 Mar 28;6(3):271-281.e7
pubmed: 29596782
Br J Cancer. 2009 Feb 24;100(4):656-62
pubmed: 19190631
J Pathol. 1999 Mar;187(4):433-8
pubmed: 10398103
Curr Colorectal Cancer Rep. 2019 Apr;15(2):61-69
pubmed: 31130830
Biochemistry. 2015 Aug 4;54(30):4583-98
pubmed: 26177309
Cancer Cell. 2018 Apr 9;33(4):676-689.e3
pubmed: 29622463
J Biol Chem. 2004 Jun 4;279(23):24505-13
pubmed: 15044465
Biochim Biophys Acta. 2007 Aug;1773(8):1263-84
pubmed: 17126425
Cancer Res. 2008 Dec 15;68(24):10086-93
pubmed: 19074874
Front Immunol. 2021 May 13;12:679090
pubmed: 34054869
Semin Cancer Biol. 2020 May;62:48-67
pubmed: 31336150
N Engl J Med. 2020 Sep 24;383(13):1207-1217
pubmed: 32955176
Genomics. 1992 Jun;13(2):481-3
pubmed: 1612609
Cell Stem Cell. 2011 Nov 4;9(5):476-85
pubmed: 22056143
Nat Rev Drug Discov. 2020 Dec;19(12):902
pubmed: 33082552
Cell. 2018 Apr 5;173(2):305-320.e10
pubmed: 29625049
Cancer Res. 2004 Jan 1;64(1):215-20
pubmed: 14729627
Cancer Discov. 2018 Jun;8(6):730-749
pubmed: 29510987
Nat Rev Drug Discov. 2014 Nov;13(11):828-51
pubmed: 25323927
Cancer Res. 2000 Dec 1;60(23):6750-6
pubmed: 11118062
Proc Natl Acad Sci U S A. 1989 Apr;86(7):2403-7
pubmed: 2648401
Curr Cancer Drug Targets. 2019;19(3):210-221
pubmed: 29984655
Mod Pathol. 2013 Oct;26(10):1346-54
pubmed: 23599154
Clin Cancer Res. 2006 Mar 1;12(5):1647-53
pubmed: 16533793
Oncoimmunology. 2018 Jan 16;7(4):e1373233
pubmed: 29632715
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
Int J Cancer. 2012 Oct 15;131(8):1810-7
pubmed: 22290300
Cancer Discov. 2013 Oct;3(10):1108-12
pubmed: 24124232
Int J Mol Sci. 2021 Jul 14;22(14):
pubmed: 34299137
Int J Gen Med. 2021 Jul 15;14:3497-3509
pubmed: 34295178
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
Cell. 1990 Jun 1;61(5):759-67
pubmed: 2188735
Semin Cancer Biol. 2019 Dec;59:23-35
pubmed: 31255772
Oncotarget. 2014 Apr 15;5(7):1885-96
pubmed: 24681892
FEBS J. 2021 Dec;288(23):6683-6699
pubmed: 34227245
Nat Commun. 2020 Oct 28;11(1):5439
pubmed: 33116132
Mod Pathol. 2007 Mar;20(3):375-83
pubmed: 17277760
J Hematol Oncol. 2021 Jul 23;14(1):116
pubmed: 34301278
PLoS One. 2013 Nov 06;8(11):e80084
pubmed: 24223213
J Immunother Cancer. 2018 Nov 19;6(1):123
pubmed: 30454021
Clin Transl Med. 2021 Mar;11(3):e306
pubmed: 33783999
J Immunol Res. 2014;2014:686879
pubmed: 24741617
Cell. 1988 May 20;53(4):549-54
pubmed: 2453289
Semin Cancer Biol. 2020 May;62:31-47
pubmed: 31412297
Cell Mol Immunol. 2021 Mar;18(3):556-565
pubmed: 33473191
FEBS J. 2017 Jan;284(1):10-26
pubmed: 27860287
J Chem Phys. 2015 Feb 14;142(6):064112
pubmed: 25681892
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
Nature. 2020 Mar;579(7800):567-574
pubmed: 32214244
FASEB J. 2021 Apr;35(4):e21461
pubmed: 33724568
Nat Methods. 2008 Jul;5(7):621-8
pubmed: 18516045
J Biol Chem. 2002 Sep 27;277(39):36118-28
pubmed: 12140283
Int J Clin Exp Pathol. 2013 Oct 15;6(11):2497-505
pubmed: 24228112
Breast Cancer Res. 2021 May 10;23(1):51
pubmed: 33966638
Signal Transduct Target Ther. 2021 Apr 9;6(1):144
pubmed: 33833221
Mod Pathol. 2011 Dec;24(12):1571-7
pubmed: 21743433
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Int J Colorectal Dis. 2019 Aug;34(8):1491-1496
pubmed: 31309326
Arch Gynecol Obstet. 2014 Mar;289(3):649-55
pubmed: 24013431
J Biol Chem. 2010 Oct 1;285(40):30419-26
pubmed: 20663889
Methods Mol Biol. 2005;294:23-9
pubmed: 15576902
Nat Rev Drug Discov. 2020 Aug;19(8):533-552
pubmed: 32528145
Matrix Biol. 2016 Jan;49:10-24
pubmed: 26163349
Cell. 2018 Apr 5;173(2):291-304.e6
pubmed: 29625048
Mol Membr Biol. 2008 Jan;25(1):72-82
pubmed: 18097955
J Clin Invest. 2005 Aug;115(8):2223-33
pubmed: 16025156
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Mol Cell Biochem. 2021 Nov;476(11):3935-3950
pubmed: 34181183
J Biol Chem. 2012 Jul 13;287(29):24320-9
pubmed: 22582394
Nat Commun. 2019 Dec 12;10(1):5679
pubmed: 31831737
Nature. 2014 Sep 18;513(7518):382-7
pubmed: 25043054
Br J Cancer. 2010 Feb 16;102(4):693-703
pubmed: 20147967
Cell. 2019 May 2;177(4):1035-1049.e19
pubmed: 31031003
Int J Cancer. 2010 Nov 1;127(9):2076-87
pubmed: 20473902
Int J Cancer. 2009 Oct 1;125(7):1626-39
pubmed: 19569244
Immunity. 2017 Dec 19;47(6):1083-1099.e6
pubmed: 29246442
Cell. 2018 Apr 5;173(2):321-337.e10
pubmed: 29625050
FEBS J. 2019 Aug;286(15):2965-2979
pubmed: 30776184
Br J Cancer. 2019 Apr;120(8):815-818
pubmed: 30862951
Nat Genet. 2019 Feb;51(2):308-318
pubmed: 30643250
Prostate. 1985;7(2):161-9
pubmed: 2413431
Semin Cancer Biol. 2019 Feb;54:1-13
pubmed: 29524560
Methods Mol Biol. 2019;1952:1-20
pubmed: 30825161

Auteurs

Karthikeyan Subbarayan (K)

Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.

Chiara Massa (C)

Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.

Sandra Leisz (S)

Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.

André Steven (A)

Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.

Daniel Bethmann (D)

Institute of Pathology, Martin Luther University Halle-Wittenberg, Halle, Germany.

Katharina Biehl (K)

Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.

Claudia Wickenhauser (C)

Institute of Pathology, Martin Luther University Halle-Wittenberg, Halle, Germany.

Barbara Seliger (B)

Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.
Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH